- Home
- REVBW
as 07-26-2024 4:00pm EST
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
| Founded: | N/A | Country: | United States |
| Employees: | 9 | City: | SAN DIEGO |
| Market Cap: | N/A | IPO Year: | 2020 |
| Target Price: | N/A | AVG Volume (30 days): | N/A |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | N/A | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Revelation Biosciences Inc. Warrant News
REVBW Breaking Stock News: Dive into REVBW Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
19 days ago
REVB Releases Positive Test Results—Potential Catalyst
Benzinga
a month ago
Why Is Nano-Cap Revelation Biosciences Stock Skyrocketing On Monday?
MT Newswires
a month ago
Revelation Biosciences Shares Jump on Positive Results for Investigational Drug Gemini
Business Wire
a month ago
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
Business Wire
a month ago
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
Business Wire
2 months ago
Net Asset Value(s)
GlobeNewswire
2 months ago
Global Automotive HMI Market Size To Worth USD 75.3 Billion By 2033 l CAGR 12.36%
Business Wire
2 months ago
Entrust Enables Governments to Transform Citizen Interactions with Digital Identities
Compare REVBW vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "REVBW Revelation Biosciences Inc. Warrant - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.